- Home
- TVTX vs SABR Comparison
TVTX vs SABR Comparison
Compare TVTX & SABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVTX
- SABR
- Stock Information
- Founded
- TVTX 2008
- SABR 2006
- Country
- TVTX United States
- SABR United States
- Employees
- TVTX N/A
- SABR N/A
- Industry
- TVTX Biotechnology: Pharmaceutical Preparations
- SABR Computer Software: Programming Data Processing
- Sector
- TVTX Health Care
- SABR Technology
- Exchange
- TVTX Nasdaq
- SABR Nasdaq
- Market Cap
- TVTX 1.5B
- SABR 1.3B
- IPO Year
- TVTX N/A
- SABR 2014
- Fundamental
- Price
- TVTX $18.37
- SABR $3.34
- Analyst Decision
- TVTX Buy
- SABR Hold
- Analyst Count
- TVTX 12
- SABR 4
- Target Price
- TVTX $24.58
- SABR $3.50
- AVG Volume (30 Days)
- TVTX 1.2M
- SABR 3.7M
- Earning Date
- TVTX 02-13-2025
- SABR 02-13-2025
- Dividend Yield
- TVTX N/A
- SABR N/A
- EPS Growth
- TVTX N/A
- SABR N/A
- EPS
- TVTX N/A
- SABR N/A
- Revenue
- TVTX $203,447,000.00
- SABR $3,001,894,000.00
- Revenue This Year
- TVTX $62.38
- SABR $6.30
- Revenue Next Year
- TVTX $57.65
- SABR $5.01
- P/E Ratio
- TVTX N/A
- SABR N/A
- Revenue Growth
- TVTX 57.08
- SABR 5.26
- 52 Week Low
- TVTX $5.12
- SABR $1.81
- 52 Week High
- TVTX $20.33
- SABR $4.60
- Technical
- Relative Strength Index (RSI)
- TVTX 52.05
- SABR 40.04
- Support Level
- TVTX $16.80
- SABR $3.19
- Resistance Level
- TVTX $18.76
- SABR $3.42
- Average True Range (ATR)
- TVTX 0.90
- SABR 0.11
- MACD
- TVTX 0.02
- SABR -0.03
- Stochastic Oscillator
- TVTX 61.57
- SABR 27.27
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2023 revenue, split between distribution (78% of segment sales) and airline IT solutions (22%) revenue. The company also has a growing hotel IT solutions division (9% of revenue). Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.